Renal Transplantation Dramatically Reduces IgA Anti-beta-2-glycoprotein I Antibodies in Patients with Endstage Renal Disease

Table 1

Etiology of endstage renal disease.

Disease	Patients (𝑁/%)	IgA aB2GPI positive*	𝑃 value	IgA aB2GPI (U/mL)**	𝑃 value
Blood donors	220	3 (1.4%)		𝟓.𝟏±𝟎.𝟒𝟒
Diabetic nephropathy	68 (23.6%)	24 (35.2%)	<0.0001	33.6±8.04	<0.0001
Glomerular disease	50 (16.0%)	8 (16.0%)	<0.0001	9.6±1.39	0.0001
Non-IgA glomerulonephritis	31 (10.7%)	2 (6.4%)	0.1165	6.6±0.85	0.1951
Berger's disease (IgA nephritis)	19 (6.5%)	6 (31.5%)	<0.0001	14.1±3.06	<0.0001
Nephroangiosclerosis	26 (9%)	10 (38.4%)	<0.0001	26.3±6.52	<0.0001
Systemic lupus erythematosus	5 (1.7%)	1 (20%)	0.0865	8.2±4.24	0.2926
Interstitial nephritis	14 (4.8%)	3 (21.4%)	0.0003	33±20.29	<0.0001
Polycystic kidney disease	31 (10.7%)	6 (19.3%)	<0.0001	12.2±2.8	<0.0001
Others (obstructive, metabolic, and others)	65 (22.5%)	19 (29.2%)	<0.0001	19.3±3.94	<0.0001
Undetermined	29 (10%)	10 (34.4%)	<0.0001	29.9±9.15	<0.0001

∗Number of patients; **mean ± standard error.